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Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are mutated 
in a variety of cancers to confer a gain-of-function activity resulting in the accumulation of an 
oncometabolite, D-2-hydroxyglutarate (2-HG). Accumulation of 2-HG can result in epigenetic 
dysregulation and a block in cellular differentiation, suggesting these mutations play a role in neoplasia. 
Based on its potential as a cancer target, a number of small molecule inhibitors have been developed 
to specifically inhibit mutant forms of IDH (mIDH1 and mIDH2). We present a comprehensive suite of 
in vitro preclinical drug development assays that can be used as a tool-box to identify lead compounds 
for mIDH drug discovery programs, as well as what we believe is the most comprehensive publically 
available dataset on the top mIDH inhibitors. This involved biochemical, cell-based, and tier-one ADME 
techniques.
The mutant isocitrate dehydrogenases 1 (mIDH1) and 2 (mIDH2) represent a remarkable example of the rapid-
ity with which target identification can translate to small-molecule drug discovery and clinical trials1,2. Wild 
type IDH1 protein forms a homodimer that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG, 
also termed 2-oxoglutarate, 2-OG), using the co-factor NADP+ 3. Studies in 2009/10 demonstrated that a subset 
of acute myelogenous leukemias (AML) and gliomas harbored heterozygous mutations at the R132 position of 
IDH1 and R140 or R172 of IDH2 (mutations in the two genes are mutually exclusive)4–7. Subsequently, it has been 
shown that >75% of low-grade gliomas and 20% of AML have mutations in IDH1 or IDH2, and mutations are 
also found in other solid tumors such as chondrosarcoma, cholangiocarcinoma, colon, pancreatic and prostate 
cancer to varying extents1,8. In fact, the world health organization (WHO) has recently added IDH genotype to 
the classification of select diffuse gliomas9.
While the R132 mutation reduces normal enzymatic activity, it also confers a neomorphic (gain-of-function) 
activity. Metabolic profiling showed that the wild type IDH1 product, α-KG, is the substrate of mIDH1, pro-
ducing D-2-hydroxyglutarate (2-HG) in a NADPH-dependent manner10. 2-HG is detected at low concentra-
tions in normal cells, yet is significantly elevated in tumor cells (up to 10 mM) and plasma of patients bearing 
IDH1/2 mutations10. Considerable evidence now exists demonstrating that the 2-HG ‘oncometabolite’ produced 
by mIDH1 plays a role in tumorigenesis and cellular proliferation11–15. 2-HG is structurally similar to α-KG and 
has been shown to inhibit α-KG-dependent enzymes, modifying the endogenous cellular biochemical balance15. 
Consequently, inhibition of α-KG-dependent histone and DNA demethylases by 2-HG leads to elevated methyl-
ation of their substrates, altered gene expression, and a block to cell differentiation16.
Inhibition of oncogenic mIDH1/2 represents an opportunity for therapeutic intervention. As a target, 
mIDH1/2 contains a distinct genetic modification allowing personalized medicine using tumor gene sequencing 
and oncometabolite detection as biomarkers17. Ideally, specific inhibition of mIDH1 or mIDH2 would have few 
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clinical side-effects, as no endogenous biochemistry would be disrupted by pharmacologic modulation. mIDH1 
and mIDH2 have therefore received significant attention for the development of small molecule inhibitors2.
Several biotech and pharmaceutical discovery campaigns for mIDH1/2 inhibitors have been disclosed. 
Many of these inhibitors are in clinical trials for patients with AML or solid tumors demonstrating the rapid 
advancement from the first report of the IDH1 mutation seven years ago to current late phase clinical trials. Agios 
Pharmaceuticals has reported the mIDH1 inhibitor AG-519818, optimized from a phenyl-glycine hit from a bio-
chemical screen19, along with a similar lead, the phenyl-glycine analog ML309, in collaboration with NCATS20. 
Agios has subsequently revealed their mIDH1 inhibitor clinical candidate, AG-120, currently in phase III21. 
Likewise, Novartis has reported multiple probe molecules and their clinical candidate, IDH30522, is currently 
in Phase I. In addition, Forma (FT-2102) and Bayer (BAY1436032) also have clinical candidate IDH1 inhibitors 
currently in Phase I23. Sanofi and GlaxoSmithKline have reported their own mIDH1 probe molecules24,25. Agios 
has also developed mIDH2 inhibitors, derived from biochemical screens to produce the heterocyclic urea sulfo-
namide probe, AGI-678026, and two clinical candidates, AG-221 (Phase III) and AG-881 (Phase I, pan-mutant 
IDH1/2 inhibitor)22. Along with these published peer-reviewed reports, additional chemotypes have been dis-
closed in patents, which have led to the development of several commercially available inhibitors with limited 
characterization.
While multiple inhibitors have been reported, some of which are available to research laboratories, the clinical 
development and proprietary nature of mIDH inhibitors has meant that limited characterization is publically 
available. In addition, the scope of activity of many of these mIDH inhibitors as pre-clinical chemical probes or 
tool molecules has not been assessed, and no insight into relative utility is currently available. To remedy this 
situation, we comprehensively characterized the activity of nine chemically diverse mIDH1 inhibitors in a panel 
of in vitro biochemical as well as functional cellular assays. Specifically, inhibitor activity was assessed in vitro 
against mIDH1 enzymes containing multiple clinically-relevant mutations. Cell-based activity was assessed by 
measurement of 2-HG production, via mass-spectrometry as well as an in-house developed high-throughput 
fluorescence assay, in cell lines harboring somatic or engineered mIDH1. Inhibitor target engagement was con-
firmed by utilizing the cellular thermal shift assay (CETSA)27. Rescue of the 2-HG induced blockade on leukemic 
differentiation was assessed to compare compound efficacy in an in vitro AML model. Three-dimensional (3D) 
culture of mIDH1 lines was developed as an in vitro solid tumor model to compare inhibitor activity via 2-HG 
production and cell growth. Finally, physicochemical and in vitro drug metabolism parameters (i.e. solubility, 
PAMPA permeability, Caco-2 cell transwell permeability, plasma protein binding, and liver microsomal stability) 
were determined. Altogether, these assays provide a comprehensive assessment of the comparative activity of the 
mIDH1 inhibitor landscape and a platform that could be implemented for future mIDH1 inhibitor discovery 
campaigns. This effort also illustrates a rigorous and general approach to addressing reproducibility in preclinical 
drug discovery through construction of a hierarchy of biological assays to assess compound suitability for clin-
ical development. Reproducibility and target validity is assessed based on replication of activity not of a single 
compound in a single assay, but rather of many compounds tested repeatedly across multiple assays with diverse 
readouts28.
Results
Biochemical characterization of mIDH1inhibitors. We characterized the activity of 9 mutant IDH1 
inhibitors (Fig. 1A–I) and 3 control mIDH2 inhibitors (Fig. 1J–L) against purified recombinant R132H and 
R132C mIDH1 enzymes, as well as the purified wild type IDH1 and IDH2 enzymes. Each enzyme was coupled 
to a diaphorase/resazurin readout for a red-shifted fluorescence detection of cofactor turnover to avoid com-
pound fluorescence interference (Fig. 2A)20,29,30. All mIDH1 inhibitors were more potent against both R132H and 
R132C mIDH1 enzymes than wild type IDH1, and were inactive against wild type IDH2 (Fig. 2B–D and Table 1). 
The most potent inhibitors against both mIDH1 enzymes were AG-120 and Novartis 530 with IC50 values of 
40–50 nM. Additionally, AG-120 and Novartis 530 revealed an 85–106 and 70–88 fold separation in potency, 
respectively, relative to wild type IDH1 (Fig. 2B–D and Table 1). A strong correlation (R2 = 0.85) was found for 
cross-inhibition of the R132H and R132C enzymes (Fig. 2E). Sanofi’s compound 1 demonstrated weak activity 
(IC50 > 13 μM) against all enzymes, and was excluded from subsequent cell-based studies. Control mIDH2 inhib-
itors demonstrated weak activity (>10 μM) against mutant and wild type IDH1 enzymes, and wild type IDH2 
enzyme (Supplemental Table 1).
Given the difficulty of predicting the physiological substrate and co-factor concentrations in target tissues and 
the fact that these are in constant flux within the cell, at times it can be beneficial to pursue non-competitive mech-
anisms of inhibition31. To determine if any of the mIDH1 inhibitors demonstrated competitive inhibition with the 
mIDH1 substrate α-KG, enzyme inhibition was assessed in the presence of high (5 mM), medium (300 µM), and 
low (125 µM) concentrations of α-KG. ML309 (Fig. 2F) and AGI-5198 (Table 1) revealed a >10-fold loss of activ-
ity in the presence of high α-KG, whereas the strongest inhibitors, AG-120 (Table 1) and Novartis 530 (Fig. 2G), 
demonstrated only a 3-4 fold IC50 shift.
Inhibition of R172Q mIDH2 enzyme was assessed for all compounds; with the characterized mIDH2 
inhibitors demonstrating strong inhibition (Supplementary Figure 1A and Supplemental Table 1). The Agios 
probe AGI-6780 (IC50 = 23 nM) was slightly more potent than the clinical candidate, AG-221 (IC50 = 65 nM), 
and demonstrated greater inhibitory activity than the patent compound IDH2-C100 (IC50 ~1 µM). None of the 
mIDH2 inhibitors demonstrated activity against the IDH1 enzymes, but the mIDH1 inhibitor GSK864 (mIDH1 
IC50 = 100–150 nM) did inhibit mIDH2 (IC50 = 183 nM).
Cellular characterization of mIDH1 inhibitors. Cellular inhibition of mIDH1 was assessed in four 
human cell lines derived from various malignancies known to harbor somatic IDH1 mutations - HT1080 
(R132C) fibrosarcoma32; SNU1079 (R132C) cholangiocarcinoma33; RBE (R132S) cholangiocarcinoma33; JJ012 
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(R132G) chondrosarcoma34 - and two cell lines engineered to express mIDH1 - U87 (R132H) glioblastoma20 and 
THP-1 (R132H) AML35 (Supplementary Table 2). Inhibition of the target was assessed by quantitative measure-
ment of 2-HG levels in extracellular media of monolayer (or 2-dimentional, 2D) cultures following incubation 
(48 hrs) with inhibitors. Baseline media 2-HG concentrations after 48 hours of incubation ranged from 167 µM 
(U87-R132H) to 13 µM (THP1-R132H) (Fig. 3A). mIDH1 inhibitors were found to be active across all cell lines, 
demonstrating similar IC50s for all cell backgrounds. Consistent with biochemical activity, the most potent inhib-
itors in all six cell lines (representing four different R132 mutations) were AG-120 and Novartis 530, with IC50 
values in the range of 50-220 nM. Interestingly, Agios probe AGI-5198 reproducibly demonstrated potent, selec-
tive inhibition in the two R132H cell lines (U87 IC50 = 40 nM and THP-1 IC50 = 50 nM) compared with other cell 
lines (>1 µM, Fig. 3B–F, Supplemental Fig. 1B–C, and Supplemental Table 1).
Among the 6 cell lines tested, two harbored the R132H mutation and two others possessed the R132C muta-
tion, allowing for a comparison of inhibitor activity against a specific R132 mutation in different cellular back-
grounds. A strong correlation was observed between inhibition in THP-1 and U87 cells (R132H, R2 = 0.81) and 
between SNU1079 and HT1080 cells (R132C, R2 = 0.93). Hierarchical clustering of cell line sensitivity (IC50) 
further supports this strong correlation by mutation type (Fig. 3H). It should be noted that this clustering could 
also be influenced by the fact that both U87 and THP-1 are the only two engineered cell lines in the panel. Cell 
Figure 1. Structures of mIDH inhibitors. (A) AG-120, (B) AGI-5198, (C) Agios 135, (D) ML309, (E) Novartis 
224, (F) Novartis 556, (G) Novartis 533, (H) GSK864, (I) Sanofi 1, (J) AGI-6780, (K) AG-221, and (L) 
IDH2-C100.
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viability was also examined at 48 hrs and no significant cytotoxicity was observed for any of the mIDH inhibitors 
(not shown).
Diaphorase-coupled high-throughput assay for measuring 2-HG levels. Quantitative 2-HG 
measurement relies primarily on mass spectrometry (MS) analysis, which is time-consuming and can be 
cost-prohibitive. To address this, we optimized a high-throughput method to quantify the effects of small mole-
cule mIDH1 inhibitors on 2-HG production levels in HT1080 mIDH1 R132C fibrosarcoma cells. Previous work 
has shown that D-2-hydroxyglutarate dehydrogenase (D2HGDH) from Acidaminococcus fermentans catalyzes 
the oxidation of 2-HG to α-KG, as well as the reduction of the cofactor NAD + into NADH as a product36. By 
modifying reaction conditions previously developed for this bacterial enzyme, we developed a system to rapidly 
enable deproteination of spent cell media, and enzymatically-couple the D2HGDH reaction with diaphorase 
activity through NADH to provide a fast and inexpensive high-throughput fluorescence assay to quantify 2-HG 
production in cells (Fig. 4A–B).
Detection limits and assay linearity were determined using a standard curve of 2-HG over a concentration 
range of 8 µM to 4 nM from which a linear relationship was determined (R2 = 0.93) (Supplemental Fig. 1D). 
Baseline 2-HG concentrations after 48 hours was 1.39 µM. Samples containing 2-HG concentrations outside this 
range will require dilution. Using the optimized assay conditions, we tested the inhibitors in 384-well plate format 
at concentrations from 47 µM to 0.8 nM. The assay demonstrated robust performance, with an average Z’ of 0.59 
Figure 2. Biochemical characterization of mIDH1 inhibitors. (A) Scheme of IDH1 and mIDH1 enzymatic 
reactions coupled to diaphorase for fluorescence detection. B-D, Dose-response analyses show the selectivity of 
mIDH1 inhibitors on the activity of purified (B) wild type IDH1, (C) R132H and (D) R132C mIDH1 enzymes 
(n = 3). (E) Comparison of mIDH1 inhibitors Log IC50 values on the activity of R132H and R132C mIDH1 
enzymes show a strong correlation (R2 = 0.85, P value = 0.001). A large dose-response shift is shown for (F) 
ML309 compared to (G) Novartis 530 when using a range of concentrations of α-KG, suggesting ML309 acts as 
a competitive inhibitor (n = 3).
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and an average signal to background ratio of 3.44, indicating the protocol is suitable for measuring 2-HG levels 
secreted from cells. AG-120 and Novartis 530 showed the greatest decrease of 2-HG levels in a dose-dependent 
manner, with IC50s of 13 nM and 34 nM, respectively (Fig. 4C). Additionally, results from the diaphorase-coupled 
assay correlated well with the MS-based 2-HG data, in terms of both biochemical IC50 values (R2 = 0.62), and 
overall rank order (R2 = 0.55) (Fig. 4D–E).
Comparison of cellular target engagement of mIDH1 inhibitors. A challenging hurdle for small 
molecule probe/drug development is the determination of cellular target engagement. Cellular thermal shift 
assays (CETSA) provide a label free biophysical method that facilitates the direct measurement of cellular target 
engagement27. In order to assess and compare the cellular target engagement of mIDH1 inhibitors, we utilized 
the engineered U87 (R132H) glioblastoma cell line. An initial cellular thermal melt analysis performed over the 
temperature range of 37–73 °C found an optimal isothermal melting temperature of 59 °C for mIDH1 R132H 
(Fig. 5A,B). An isothermal dose-response (100–0.02 µM) of the panel of mIDH1 inhibitors was then performed 
at 59 °C for 3 minutes (Fig. 5C,D). Target engagement resulted in stabilization of mIDH1 protein compared with 
DMSO (Fig. 5C). Area under the curve (AUC) analysis for each dose-response curve revealed that while a major-
ity of the inhibitors induced strong thermal stabilization of mIDH1-R132H, AG-120 and Novartis 530 are among 
the top compounds (Fig. 5E). With respect to the other mIDH1 assays, IC50 values in the CETSA assay demon-
strated a lack of correlation with IC50s in the biochemical R132H assay (R2 = 0.18), while a stronger correlation 
was seen between CETSA and cellular (U87-R132H) mIDH1 inhibition (R2 = 0.54) (Fig. 5F,G). Interestingly, this 
correlation greatly increases (R2 = 0.78) when AGI-5198 was excluded from the analysis.
mIDH1 inhibitors increase monocyte differentiation in mIDH1 expressing THP1 leukemia 
cells. High levels of 2-HG have been shown to repress expression of lineage-specific differentiation genes, 
block cell differentiation, and correlates with an increase in repressive histone methylation marks37. Inhibitors of 
mIDH enzymes have been shown to induce differentiation of mIDH bearing AML cell lines and primary patient 
cells24. In order to compare the ability of mIDH1 inhibitors to induce differentiation of AML cells, we imple-
mented a cell differentiation assay using human THP1 leukemia cells engineered to express either wild type IDH1 
(THP1-WT) or mIDH1-R132H (THP1-R132H) under a doxycycline-inducible promoter35,38. Mutant or wild 
type IDH1 gene expression was induced with doxycycline (0.5 µM) for four days prior to the induction of mono-
cytic differentiation with phorbol-12-myristate-13-acetate (PMA) (50 nM), ultimately resulting in cellular adher-
ence (Fig. 6A shows a schematic representation of the experiment and results). Differentiation was determined 
by imaging and quantifying the number of cells that adhered to each well in a 96-well plate (Fig. 6B,C). After 
treatment with PMA, THP1 (R132H) cells were found to have reduced levels of adherent cells compared to THP1 
(WT), indicating that high 2-HG levels may block cell differentiation (Fig. 6C). While there is a decrease in cel-
lular growth after PMA treatment when comparing THP1 (WT) and THP1 (R132H) (Supplemental Fig. 3A,B), 
this reduction did not affect cellular adhesion numbers (Fig. 6C). Treatment of the THP1 (R132H) cell line with 
0.5 µM of mIDH1 inhibitors revealed an increase in the number of adherent cells compared to DMSO alone 
(Fig. 6D and Supplemental Fig. 2). Additionally, co-treatment of THP1 (R132H) cells with the cell-permeable 
octyl-2-HG and mIDH1 inhibitors, specifically Novartis 530 and AG-120, greatly diminished the number of 
differentiated cells compared to mIDH1 inhibitor treatment alone, confirming elevated 2-HG levels are capable 
of blocking THP1 differentiation (Fig. 6E).
Given that excess 2-HG levels have been shown to increase methylation through inhibition of cellular 
demethylases, histone tri-methylation levels were examined in treated and untreated THP1 cells. H3K9me3 
and H3K4me3 levels were found to be increased in THP1 (R132H) cells compared to THP1 (WT) cells. 
mIDH1 
Inhibitor Organization
Clinical 
Trials
Biochemical α-ketoglutarate Shift
IDH1 R132H IDH1 R132C IDH1 WT IDH2 WT
5000 µM 
α-KG
125 µM 
α-KG
Fold Shift
EC50 
(µM) % EMax
EC50 
(µM) % EMax
EC50 
(µM) % EMax
EC50 
(µM) % EMax
EC50 
(µM)
EC50 
(µM)
AG-120 Agios Phase III 0.04 ± 0.01 108.2 ± 1.2 0.05 ± 0.02 103.4 ± 5.0 4.26 ± 0.46 74.5 ± 3.2 >30.00 24.7 ± 6.7 0.21 ± 0.04 0.05 ± 0.00 4.34
Novartis 
530 Novartis Unknown 0.05 ± 0.01 105.7 ± 1.7 0.04 ± 0.00 99.5 ± 3.5 3.51 ± 0.17 102.1 ± 5.8 >30.00 17.3 ± 4.4 0.10 ± 0.01 0.03 ± 0.00 3.04
Novartis 
224 Novartis Unknown 0.13 ± 0.02 107.4 ± 2.9 0.09 ± 0.02 100.0 ± 1.6 3.87 ± 0.40 103.8 ± 3.8 >30.00 19.4 ± 11.4 0.52 ± 0.04 0.08 ± 0.00 6.57
Norvatis 
556 Novartis Unknown 0.14 ± 0.03 107.2 ± 2.6 0.19 ± 0.03 102.2 ± 2.0 10.5 ± 1.01 90.0 ± 7.4 >30.00 20.7 ± 5.4 0.88 ± 0.06 0.19 ± 0.02 4.63
GSK864 GSK No 0.16 ± 0.01 109.7 ± 1.9 0.10 ± 0.01 98.4 ± 3.7 2.74 ± 0.32 81.5 ± 2.6 >30.00 23.9 ± 2.3 0.69 ± 0.00 0.19 ± 0.00 3.55
ML309 NCATS/Agios No 0.34 ± 0.00 99.9 ± 3.7 0.09 ± 0.02 94.9 ± 3.1 20.9 ± 1.22 42.6 ± 2.6 >30.00 18.8 ± 7.7 0.62 ± 0.08 0.06 ± 0.00 10.0
Agios 135 Agios No 0.38 ± 0.00 102.7 ± 2.4 0.09 ± 0.01 97.4 ± 5.3 15.6 ± 2.76 43.4 ± 4.2 >30.00 18.0 ± 7.1 0.18 ± 0.03 0.08 ± 0.00 2.43
AGI-5198 Agios No 0.39 ± 0.04 104.6 ± 1.6 1.28 ± 0.30 95.8 ± 5.8 >30.00 15.2 ± 4.0 >30.00 25.2 ± 9.5 13.3 ± 0.00 1.24 ± 0.08 10.9
Sanofi 1 Sanofi No 13.4 ± 1.38 69.1 ± 5.1 13.6 ± 1.17 54.0 ± 7.6 >30.00 18.8 ± 2.2 >30.00 19.9 ± 8.0 >30.000 11.9 ± 0.00 N/A
Table 1. Biochemical Profile of mIDH1 Inhibitors.
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Figure 3. Activity of mIDH1 inhibitors in 2D cellular models. (A) Average concentration of 2-HG in media 
produced by mIDH1 containing cell lines cultured in 2D after 48 hrs. Bars represent average and SD of 2-HG 
concentrations determined by mass spectrometry analysis (n = 11–12). Dose-response analysis of mIDH1 
inhibitor effects on cellular 2-HG production in, (B) HT1080 (R132C), (C) RBE (R132S), (D) JJ012 (R132G) 
(E) U87(R132H) cell lines (n = 3). (F) Comparison of mIDH1 inhibitor Log IC50 values from THP1 (R132H) 
and U87 (R132H) cell lines show a strong correlation (R2 = 0.81, P value = 0.002). (G) Comparison of mIDH1 
inhibitor Log IC50 values from SNU1079 (R132C) and HT1080 (R132C) cell lines show a strong correlation 
(R2 = 0.93, P value = 0.0001). (H) Heat map of Log IC50 values of mIDH1 inhibitors from all six cell lines. Cell 
line dendrogram was generated using the UPGMA clustering method with Euclidean distance measures.
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Furthermore, treatment of THP1 (R132H) cells with either Novartis 530 or AG-120 reduced these elevated levels 
of tri-methylation (Fig. 6F and Supplemental 1E–F).
mIDH1 inhibitors reduce 2-HG levels in spheroid models. To evaluate the effect of mIDH1 inhibitors 
in more relevant models of solid tumors, we adapted a 3-dimensional (3D) multicellular tumor spheroid assay to 
monitor spheroid formation and 2-HG production. Small molecules can have diminished efficacy in multicellular 
tumor spheroid models due to limited penetration and the heterogeneous nature of the 3D tumor spheroid39,40. 
We began by testing the 6 aforementioned cell lines for their ability to form spheroids in ultra-low attachment 
plates at varying cell concentrations (1000–5000 cells/well). Four cell lines (HT1080 fibrosarcoma, JJ012 chon-
drosarcoma, U87 glioblastoma and RBE cholangiocarcinoma), each with a different R132 mutation, were shown 
to form spheroids (Fig. 7A). Overall, spheroids produced less extracellular 2-HG than cells cultured in monolayer 
(Fig. 7B).
Using these simple 3D models of solid tumors, we assessed the ability of inhibitors to reduce 2-HG produc-
tion. All mIDH1 inhibitors tested demonstrated complete suppression of 2-HG against all cell lines except the 
RBE cells (Fig. 7C–G), which had reduced efficacy and no effect on rank-order of potency. Interestingly, AG-120 
and Novartis 530 were the two most efficacious inhibitors in both monolayers (2D) and 3D cultures (Fig. 7G–I). 
Moreover, the activity of inhibitors in 2D and 3D models demonstrated strong positive correlations, particularly 
in the HT1080 (R2 = 0.95) and U87 (R2 = 0.86) cell lines (Fig. 7H,I).
In vitro drug metabolism and pharmacokinetic properties of mIDH inhibitors. Drug metab-
olism and pharmacokinetic properties of probe compounds and drug candidates ultimately determine how 
these compounds behave/perform in preclinical animal models and clinical trials41. Using robust, automated, 
high-throughput in vitro assays, we measured the solubility, permeability, metabolic stability, and plasma 
protein binding properties for the panel of mIDH1 inhibitors. Aqueous solubility of the mIDH1 inhibitors 
was assessed using a kinetic solubility determination in an aqueous solution at pH 7.442. While a wide range 
of solubilities were observed (<0.1–147.9 µM), only Agios 135 and GSK864 had solubility concentrations that 
approached their respective IC50 values from the 2-HG cell-based assay (Supplemental Table 1). On the other 
Figure 4. Detection of 2-HG using a fluorescent D-2-Hydroxyglutarate Dehydrogenase (D2HGDH) enzymatic 
assay. (A,B) Scheme of the cell-based diaphorase coupled D2HGDH assay. Media was transferred to a new plate 
48 hours after cells were plated and compounds were added. Following a deproteination step, D2HGDH enzyme 
reaction mix was added for fluorescent quantitation of 2-HG concentrations. (C) Dose-response analysis of 
mIDH1 inhibitor effects on 2-HG production utilizing the D2HGDH assay (n = 2). (E) Comparison of mIDH1 
inhibitor Log IC50 values observed from mass spectrometry analysis (MS) and the D2HGDH assay (R2 = 0.63, P 
value = 0.019). (F) Comparison of rank order based on Log IC50 values of mIDH1 inhibitors generated from MS 
analysis and the D2HGDH assay (R2 = 0.55, P value = 0.036).
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hand, Novartis 530 and AG-120 had the greatest separation between solubility and IC50 values. Parallel arti-
ficial membrane permeability assays (PAMPA) were used to model passive, transcellular permeability across 
the gastrointestinal tract (GIT)43. All compounds tested were characterized as highly permeable (>100 × 10−6 
Figure 5. mIDH1 inhibitors increase the thermal stability of cellular mIDH1 (R132H) enzyme in the 
cellular thermal shift assay. (A) Densitometry analysis of mIDH1 enzyme after a cellular thermal melt of U87 
(R132H) cells (n = 2) demonstrates 59 °C as an optimal temperature for isothermal dose-response analysis. 
(B) Representative western blot of the cellular thermal melt of U87 (R132H) cells using a temperature range 
of 37 °C–73 °C. (C) Represented western blot of an isothermal dose-response at melting temperature of 59 °C 
demonstrating cellular mIDH1 enzyme thermal stabilization with mIDH1 inhibitors. (D) Isothermal dose-
response analysis of mIDH1 inhibitors’ stabilization of the cellular mIDH1 enzyme (n = 4). (E) Area under the 
curve analysis derived from the isothermal dose response curves. (F) Comparison of mIDH1 inhibitor Log EC50 
values from the biochemical assay (mIDH1 (R132H)) and the cellular thermal shift assay shows no correlation 
(R2 = 0.18, P value = 0.234). (G) Comparison of mIDH1 inhibitor Log EC50 values from the cellular assay 
(U87(R132H)) and the cellular thermal shift assay shows a correlation (R2 = 0.54, P value = 0.038).
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Figure 6. mIDH1 inhibitors rescue monocytic differentiation and histone methylation of mIDH1 expressing 
THP1 leukemic cells. (A) Schematic representation of the differentiation assay. Engineered THP1 cells 
grown in suspension were treated with doxycycline to induce WT IDH1 (top) or mIDH1-R132H (middle) 
expression followed by PMA to induce differentiation. Induction of mIDH1 increases 2-HG levels, alters 
histone methylation, and blocks differentiation. mIDH1 inhibitors block mIDH1 activity and reduce 2-HG 
(bottom), allowing for the rescue of PMA induced monocytic differentiation. (B) Representative images of 
adherent doxycycline induced THP1 IDH1 (WT) cells treated for 7 days with DMSO (left) or PMA (right) 
(scale = 200 µm). (C) Number of adherent THP1 leukemic cells expressing either WT or mIDH1 R132H after 
7 days of treatment with DMSO or 50 nM PMA. Bars represent average and SD of number of adhered cells / 
well (n = 16). (D) Number of adherent mIDH1 expressing THP1 leukemic cells after 5 days of treatment with 
either DMSO or 50 nM PMA following 4 days of treatment with 500 nM of mIDH1 inhibitors. Bars represent 
average and SD of number of adhered cells / well (n = 16). (E) Number of adherent mIDH1 expressing THP1 
leukemic cells after 5 days of treatment with either DMSO or 50 nM PMA following 4 days of treatment with 
50 µM mIDH1 inhibitors in the presence or absence of 300 µM octyl-2-HG. (F) Representative western blot 
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cm/s) (Supplemental Table 1). Hepatic microsomal stability half-life (t1/2) values in three species (mouse, rat and 
human) were determined using a multiple time-point metabolic stability assay44. AG-120 had the highest meta-
bolic stability, while the rest of the mIDH1 inhibitors were classified as low stability compounds with t1/2 less than 
10 min (Supplemental Table 1). Human plasma protein binding revealed a very high (>96%) protein binding for 
most mIDH1 inhibitors, while AG-120 and Novartis 556 demonstrated the greatest unbound fractions (~10% 
unbound) (Supplemental Table 1). Caco-2 permeability was measured to gain insight into potential interactions 
with membrane transporters. While Agios 135 and AGI-5198 had increased efflux ratios suggesting potential 
interactions with membrane transporters, AG-120 demonstrated the highest efflux ratio at 56 with very low apical 
to basal transport (Supplemental Table 1).
The apparent basal to apical transport of AG-120 in Caco-2 cells was suggestive of an active drug transporter 
such as the multidrug transporter P-glycoprotein (P-gp, MDR1, ABCB1)45. AG-120 is in human clinical trials, 
where P-glycoprotein at the blood-brain barrier (BBB) might limit drug uptake in the CNS46. To investigate this, 
transwell transport of AG-120 was also assessed in MDCK cells transfected with P-gp. AG-120 demonstrated 
strong basolateral to apical transport and almost no apical to basolateral transport. This imbalance was completely 
reversed in the presence of the P-gp small molecule inhibitors tariquidar and verapamil (Supplemental Fig. 3C). 
For comparison, AG-120 demonstrated a greater efflux ratio (AG-120 efflux ratio >350) than the avid P-gp sub-
strate loperamide (efflux ratio ~350), which cannot cross the BBB (Supplemental Figure 3D)47.
In vitro predictive toxicity assays were also utilized to determine if mIDH1 inhibitors may cause cytotoxicity 
in human hepatoyctes or inhibit hERG channels48. All mIDH1 inhibitors show little to no cytotoxicity after 72 hr 
incubation with human hepatocytes, except at the highest doses tested (46 µM) (Supplemental Fig. 3E). Activity 
at the well-known anti-target, the hERG channel, was assessed using the hERG FluxOR-based thallium flux assay. 
All compounds tested had IC50 values above 10 µM except for GSK864 (IC50 = 4.7 µM) (Supplemental Fig. 3F).
Discussion
There are multiple mIDH1/2 inhibitors currently in clinical trials49. Agios has made the most progress, advanc-
ing its mIDH2 inhibitor, AG-221 (Enasidenib), into a phase III open-label clinical trial in 14 countries for late 
stage AML harboring an IDH2 mutation (NCT02577406) and it was approved by the FDA in August 2017. 
Agios has also advanced its mIDH1 inhibitor, AG-120 (Ivosidenib), into a phase III clinical trial for metastatic 
cholangiocarcinoma (NCT02989857). Additionally, Agios is pursuing a brain-penetrant dual mIDH1/2 inhib-
itor, AG-881, currently in phase I for advanced solid tumors including gliomas containing an IDH1/2 muta-
tion (NCT02481154). Bayer (BAY1436032), Novartis (IDH305), and Forma Therapeutics (FT-2102) all have 
mIDH1 inhibitors currently in phase I clinical trials for either solid tumors or refractory AML (NCT02746081, 
NCT02381886, and NCT02719574). Recently, Bayer disclosed the structure of their clinical mIDH1 inhibitor 
BAY 1436032, showing favorable oral pharmacokinetic properties, reasonable brain barrier penetration, and 
a direct interaction with the mutational residue His132 of the mutant IDH1 R132H enzyme50. Novartis also 
recently published an optimized mutant IDH1 inhibitor (IDH889) similar to the chemotype studied here, with 
favorable oral pharmacokinetic properties and brain barrier penetration51. Several inhibitor classes were not 
available to us at the time this study was undertaken, including the Bayer (BAY1436032), Forma (FT-2102), and 
Novartis (IDH305 and IDH889) inhibitors previously mentioned.
This assessment of multiple mIDH inhibitors across many in vitro assay platforms characterizes the compar-
ative activities of these mIHD1/2 inhibitors. AG-120 and Novartis 530 rank the highest when observing bio-
chemical potencies, reduction of 2-HG in all six cell lines, and when measuring isothermal dose response using 
CETSA. Novartis 530 and 224 show the best activity in reversing 2-HG dependent differentiation of THP1 leu-
kemic cells, while AG-120’s activity is much weaker in this assay. AG-120 has the best in vitro physicochemical 
and drug metabolism profile of all the compounds tested, yet it is a substrate for P-gp transporters preventing its 
passage through the BBB. This study identifies appropriate inhibitors for studying mIDH1/2 enzymes and their 
role in the pathophysiology of certain diseases. It also provides an opportunity to confirm that the biochemical 
and cell-based models utilized in previous studies are comparable. This is not necessarily clear from the literature, 
where individual lines have been used when reporting specific inhibitor activities. ML309 and initial Agios probes 
were characterized biochemically using mIDH1 R132H and mR132C homodimer protein, and in U87 (R132H) 
cells and HT1080 cells20. HT1080 cells were one of the first cell lines reported to carry a somatic IDH1 mutation32. 
Even though the prevalence of IDH mutations are very high in gliomas, mIDH1 or mIDH2 low-grade glioma cell 
lines have been difficult to generate (the TS603 oligodendroglioma harbors an IDH1 R132H mutation and grows 
as neurospheres rather than monolayer)1,18, leading to the use of a variety of transfected GBM cell lines. AGI-
5198 activity was reported against mutant/wild type IDH1 heterodimer protein and the aforementioned TS603 
cell line18. The GSK321 inhibitor was assessed against three mutant forms of protein (R132H, C and G), and in 
HT1080 cells24. The Sanofi inhibitor was assessed against a range of mIDH1 homo- and hetero-dimer protein, 
and in HEK293 cells transfected with mIDH1 (R132H)25. The mIDH2 inhibitor AGI-6780 was assessed in HEK 
cells transfected with R140Q IDH226. Here, we report the first side-by-side comparison of a diverse set of mIDH1 
inhibitors across multiple in vitro assay platforms.
Comparative efficacy of multiple chemotypes against an individual target is not commonly undertaken, but 
given the strong interest in mIDH as an oncotarget and rapid emergence of multiple parallel inhibitor develop-
ment programs, we were interested in how these chemotypes compared in assays that reported on target activity 
from purified histones showing changes in H3K9me3 and H3K4me3 methylation levels in wild type IDH1 and 
mIDH1 expressing THP1 leukemic cells after 4 days of doxycycline following treatment with either vehicle, AG-
120 (1), or Novartis 530 (2) (n = 2).
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from biochemical to cellular. A side-by-side comparison of available small molecules against multiple cell lines 
may appear to be designed to identify the ‘best’ inhibitor. However, it is important to comprehensively evalu-
ate these compounds to better understand their respective limitations; the availability of multiple mIDH1 and 
mIDH2 inhibitors will help ensure that observed phenotypes for individual compounds are truly on-target. The 
majority of inhibitors demonstrated activity in line with published reports, though in our hands the Sanofi inhibi-
tor was not as efficacious. The AG-120 and Novartis 530 were the most active across a majority of assay platforms.
We found that inhibition across multiple IDH1 mutations was generally consistent, and that this translated to 
cellular inhibition of mIDH1, both in engineered and somatic cell lines. In addition, we miniaturized a D2HGDH 
florescence-based assay to determine 2-HG concentrations in cell medium. This assay provides an accessible 
platform for research laboratories to measure 2-HG without the need for quantitative MS. We utilized the assay 
developed by Jorg Balss and colleagues that coupled the D2HGDH enzyme to resazurin to measure intracel-
lular and extracellular 2-HG36. Adnan Elhammali and colleagues subsequently reported an HTS screen using 
a similar approach in which they showed that Zaprinast reduces 2-HG by perturbing glutamine metabolism, 
Figure 7. Activity of mIDH1 inhibitors in 3D cellular spheroids. (A) Representative images of 3D cellular 
spheroids of HT1080 (top left), JJ012 (top right), U87 (R132H) (bottom left), and RBE (bottom right) cells 
(scale = 500 µm). (B) Concentration of 2-HG in media produced from 3D cellular spheroid cultures after 
4 days. Bars represent average and SD of 2-HG concentrations determined by MS analysis (n = 12). Dose-
response analysis of mIDH1 inhibitor effects on 2-HG production in (C) HT1080(R132C), (D) U87(R132H), 
(E) JJ012(R132G), (D) RBE(R132S) 3D cellular spheroids (n = 3). (G) Heat map of Log IC50 values of mIDH1 
inhibitors from the four 3D cellular spheroids. Cell line dendrogram was generated using the UPGMA 
clustering method with Euclidean distance measures. (H) Comparison of mIDH1 inhibitor Log IC50 values 
between 2D and 3D HT1080 (R132C) cellular assays show a strong correlation (R2 = 0.95, P value =  < 0.0001). 
(I), Comparison of mIDH1 inhibitor Log IC50 values between 2D and 3D U87 (R132H) cellular assays show a 
strong correlation (R2 = 0.86, P value = 0.0009).
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although the HTS assay utilized E. coli PHGDH, whose primary substrate is 3-phosphoglycerate limiting its util-
ity as a specific reporter assay52. The D2HGDH-coupled assay used here was cost effective, readily scaled down 
and semi-automated with liquid-handling, providing a high-throughput convenient method to quickly analyze 
2-HG containing media samples from cells. Like all assays, as conditions are modified by different cell types, this 
assay will need to be re-optimized.
CETSA is a relatively new assay used to interrogate target engagement independent from function53, and we 
found it to be generally informative of mIDH1 engagement and correlated to cellular inhibition of mIDH1. This 
correlation is most likely due to both assays containing a cellular context in which the inhibitors have to cross the 
plasma membrane and then engage the target in order to alter the assay readout. Given the opportunity to use 
2-HG as a biomarker in vivo (along with MRI modalities), mIDH1 may provide a strong opportunity to correlate 
xenograft target engagement using CETSA with target inhibition. The development of 3D tumor spheroids gen-
erated from cell lines (reported here) demonstrated that 2-HG production is measureable, and inhibitor efficacy 
was retained in solid tumor models and correlated with activity in monolayer cells. Interestingly, the greatest 
divergence from ranked activity was observed in the differentiation assay where AG-120 had reduced efficacy in 
rescuing the differentiation phenotype. While AG-120 demonstrated superior physicochemical and drug metab-
olism properties, its susceptibility to transport by P-gp may limit activity in drug-resistant mIDH1 cells, and may 
restrict brain penetrance54. Our panel of assays, some of which are novel and amenable for high-throughput, 
provide a comprehensive platform for drug discovery campaigns to identify additional mIDH1 inhibitors.
Materials and Methods
Compounds. Novartis 224 (HY-18717), Novartis 556 (HY-13972), Agios 135 (HY-12475), and AG-221 (HY-
18690) were purchased from Medchem Express. AGI-5198 (14624) and AGI-6780 (14639) were purchased from 
Cayman Chemicals. IDH2-C100 was purchased from XcessBio. AG-120 was purchased from CG Biopharma. 
GSK864 was a gift from Structure Genomics Consortium24. ML309 was synthesized as previously described20. 
The synthesis of Sanofi 1 and Novartis 530 are reported in the supplemental methods.
IDH1 and IDH2 biochemical assays. WT IDH1 protocol was performed as previously described20. 
Generally, WT IDH1/2 enzyme in assay buffer was added to the black solid bottom 1,536-well assay plate. A 
pintool (Kalypsys) was used to transfer 23 nL of compound solution (library and control) to the 1,536-well assay 
plates. After 30 min of incubation at room temperature, 1 μL of substrate buffer was added to initiate the reaction. 
The plate was rapidly transferred to a ViewLux (PerkinElmer) and the fluorescence product resorufin was meas-
ured in kinetic mode. Additional details are described in supplemental methods.
mIDH1-R132H and m IDH-R132C enzyme assay. mIDH1 protocol was performed as previously 
described20. Generally, 3 μL of mutant enzyme in assay was added to the black solid bottom 1,536-well assay plate. 
A pintool (Kalypsys) was used to transfer 23 nL of compound solution (library and control) to the 1,536-well 
assay plates. After 30 min incubation at room temperature, 3 μL of buffer containing NADPH and α-KG was 
added to initiate the reaction. After a 40-50 min incubation period, 3 μL of detection buffer was added to a total 
volume of 9 μL. The plate was transferred to an Envision (PerkinElmer) after 5 min and the fluorescence product 
resorufin was measured. Additional details are described in supplemental methods.
mIDH2-R170Q enzyme assay. Reaction Biology profiled all compounds against mIDH2-R172Q using a 
diaphorase / resazurin coupled reaction.
Cell culture. U87 (R132H) and HT1080 were obtained from Agios, THP1 (WT and R132H) were obtained 
from Ravindra Majeti (Stanford University), SNU1079 and RBE from Nabeel M. Bardeesy (Harvard University), 
and JJ012 were obtained from Karina Galoian (University of Miami). Short tandem repeat analysis was performed 
on each cell line using WiCell Research Institute and Genetic Resources Core Facility at the University Johns 
Hopkins (Supplemental Table 2). Additional cell culture and 2-HG production assay details are described in 
supplemental methods.
Diaphorase coupled D-2-Hydroxyglutarate Dehydrogenase Assay. The diaphorase coupled 
D-2-hydroxyglutarate dehydrogenase assay was a modification of the report by Jorg Balss and colleagues36. 
HT1080 cells (4,000 cells/well) were dispensed into 384-well TC-treated cell culture plates. A pintool (Kalypsys) 
was used to transfer 96 nL of compound solution to the 384-well assay plates. After 48 hr incubation at 37 °C, 
10 µL of media was transferred to new 384-well white solid bottom assay plates. Collected media was neutral-
ized and 36 µL of detection solution (containing active recombinant D2HGDH) was then added to the 12 µL of 
neutralized media. After 30 min incubation at room temperature, the plates were transferred to a Viewlux HTS 
Microplate Imager (PerkinElmer) and the fluorescence product resorufin was measured. Additional details are 
described in supplemental methods.
Cellular thermal shift assays. The cellular thermal shift assay and the isothermal dose response was run as 
previously described55. Additional details are described in supplemental methods.
THP1 monocytic differentiation assay. Human THP1 leukemia cells engineered to express either 
wild type IDH1 or mutant IDH1-R132H under a doxycycline-inducible promoter have been previously 
described35. To induce transgene expression, cells were treated with doxycycline (2 μg/mL final). After 4 days 
of doxycycline induction, cells were pre-treated with either vehicle DMSO or the indicated mIDH1 inhibitor at 
a final concentration of 0.5 μM for 4 additional days. Monocyte differentiation was induced by the addition of 
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phorbol-12-mysistate-13-acetate (PMA) following a previously described protocol38 with some modifications. 
Attached cells were washed, stained, imaged and quantified. Additional details are described in supplemental 
methods.
Histone methylation assay. Human THP-1 leukemia cells were grown as previously described. Following 
treatment, cells (6 × 106) were then collected, pelleted, and snap frozen. Total histone extracts were prepared 
using a Histone Extraction Kit (Abcam #113476). Extracts (7µg) were separated on 4–12% Bis-Tris NuPAGE gels 
(Thermo Fisher) and transferred to nitrocellulose membranes using an iBlot transfer system (Thermo Fisher). 
Primary antibodies were diluted in TBST + 5% BSA and incubated overnight at 4 °C: mouse anti-H3K4me3 
(Abcam #1012; 1:500), rabbit anti-H3K9me3 (Cell Signaling #13969; 1:1000) and rabbit anti-total H3 (Cell 
Signaling #4499; 1:2000). Membranes were washed 3 × 10 min with TBST and incubated with HRP-conjugated 
secondary antibodies (1:5000 in TBST + 1% BSA) for 1 hr at room temperature. SuperSignal West Dura chemi-
luminescence substrate (Thermo Fisher) was added and immunoblots were imaged using a BioRad ChemiDoc 
Imager. Densitometric analysis was performed using ImageJ. Additional details are described in supplemental 
methods.
In Vitro Physicochemical and Drug Metabolism Studies. High-Throughput PAMPA assay, 
High-Throughput kinetic solubility test assay, Microsomal metabolic stability assay, Human plasma protein bind-
ing assay, Caco-2 permeability assay, Bidirectional MDCK-MDR1 permeability assay details are described in 
supplemental methods.
Data availability. The datasets generated during and/or analyzed during the current study are available in 
the supplemental files and from the corresponding author on reasonable request.
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